Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – Current and future perspectives
journal contributionposted on 13.07.2021, 04:25 by D Prakoso, M Tate, MJ de Blasio, Rebecca RitchieRebecca Ritchie
Diabetes increases the prevalence of heart failure by 6–8-fold, independent of other comorbidities such as hypertension and coronary artery disease, a phenomenon termed diabetic cardiomyopathy. Several key signalling pathways have been identified that drive the pathological changes associated with diabetes-induced heart failure. This has led to the development of multiple pharmacological agents that are currently available for clinical use. While fairly effective at delaying disease progression, these treatments do not reverse the cardiac damage associated with diabetes. One potential alternative avenue for targeting diabetes-induced heart failure is the use of adeno-associated viral vector (AAV) gene therapy, which has shown great versatility in a multitude of disease settings. AAV gene therapy has the potential to target specific cells or tissues, has a low host immune response and has the possibility to represent a lifelong cure, not possible with current conventional pharmacotherapies. In this review, we will assess the therapeutic potential of AAV gene therapy as a treatment for diabetic cardiomyopathy.
This work was supported by the National Health and Medical Research Council (NHMRC) of Australia, in the form of a Senior Research Fellowship to RHR [grant number ID1059960] and a Project Grant [grant number ID 1158013 (to R.H.R. and M.J.D.) ] .
PublisherPORTLAND PRESS LTD
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
Science & TechnologyLife Sciences & BiomedicineMedicine, Research & ExperimentalResearch & Experimental MedicineIMPROVES CARDIAC-PERFORMANCELEFT-VENTRICULAR FUNCTIONCALCIUM UP-REGULATION3 GENE-TRANSFERHEART-FAILUREVIRUS VECTORCARDIOVASCULAR-DISEASEINCREASES FUNCTIONENDOTHELIAL-CELLSNONHUMAN-PRIMATESAAVDiabetic CadiomyopathyGene TherapydiabetesCardiovascular System & Hematology